John Misasi - Concepedia

Author

John Misasi

National Institute of Allergy and Infectious Diseases ORCID

Also Known As

Christopher L. Case, John Misasi, John N Misasi, John N. Misasi, Stephen Migueles

Publications

3.9K

Citations

H-Index

Concepts

All Affiliations

National Institute of Allergy and Infectious Diseases National Institutes of Health Frederick National Laboratory for Cancer Research Leidos (United States)Harvard University

About

John Misasi is an author at National Institute of Allergy and Infectious Diseases specializing in medicine, immunology, and virology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	14	1.7K
2	Education	1	1	71
3	Engineering	1	1	72
4	Natural Sciences	1	1	27
5	Biomolecular Engineering	1	1	72

John Misasi

Publications

3.6K

Citations

H-Index

Page 1

	Year	Citations
Small molecule inhibitors reveal Niemann–Pick C1 is essential for Ebola virus infection Marceline Côté, John Misasi, Tao Ren, Nature Small Molecule InhibitorsNiemann–pick C1MedicineAntiviral Drug DevelopmentAntiviral Therapy	2011	680
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants Kathryn Westendorf, Stefanie Žentelis, Lingshu Wang, Cell Reports	2022	452
Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody Davide Corti, John Misasi, Sabue Mulangu, Science	2016	416
Structural and molecular basis for Ebola virus neutralization by protective human antibodies John Misasi, Morgan S. A. Gilman, Masaru Kanekiyo, Science	2016	215
Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants Lingshu Wang, Tongqing Zhou, Yi Zhang, Science	2021	212
Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529 Tongqing Zhou, Lingshu Wang, John Misasi, Science VaccinationVirus StructureSars-cov-2 VariantsRbd RidgePotent Neutralization	2022	169
Functional interrogation and mining of natively paired human VH:VL antibody repertoires Bo Wang, Brandon J. DeKosky, Morgan R. Timm, Nature Biotechnology ImmunogeneticsAutoimmune DiseaseHuman Leukocyte AntigenHuman VhMedicine	2018	139
Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization Nicole A. Doria‐Rose, Xiaoying Shen, Stephen D. Schmidt, VaccinationVaccine SafetyVaccine DevelopmentMedicineVaccine Surveillance	2021	129
Filoviruses Require Endosomal Cysteine Proteases for Entry but Exhibit Distinct Protease Preferences John Misasi, Kartik Chandran, Jinyi Yang, Journal of Virology	2012	127
Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study Martin R. Gaudinski, Emily E. Coates, Laura Novik, The Lancet VaccinationOpen-label Phase 1Vaccine TargetImmunologyAntiviral Drug Development	2019	123

Page 1